-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15th, Merck (MSD) announced that its blockbuster PD-1 inhibitor pembrolizumab (trade name: Keytruda) has been approved by the China National Medical Products Administration (NMPA) for single-drug use KRAS, NRAS and BRAF genes are the first-line treatment for patients with wild-type, unresectable or metastatic high microsatellite instability (MSI-H) or mismatch repair gene defect (dMMR) colorectal cancer (CRC)
.
According to the press release, Pembrolizumab is currently the only single-drug PD-1 inhibitor approved for the first-line treatment of this type of MSI-H/dMMR advanced colorectal cancer in China
.
The approval of the new indication for pembrolizumab is based on data from the key global phase 3 clinical trial KEYNOTE-177
.
In this phase 3 clinical trial, pembrolizumab single-agent treatment of patients with MSI-H or dMMR unresectable or metastatic colorectal cancer can reduce the risk of disease progression or death by 40%, and the median progression-free survival It was 16.
